Josep M Llibre

Summary

Publications

  1. ncbi request reprint Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir
    Josep M Llibre
    Internal Medicine Department, Hospital de Calella, Barcelona, Spain
    AIDS 20:1407-14. 2006
  2. ncbi request reprint [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]
    Josep Maria Llibre-Codina
    Servicio de Medicina Interna, Hospital Sant Jaume, Calella, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:98-107. 2007
  3. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
  4. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
  5. doi request reprint Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Antimicrob Chemother 67:1462-9. 2012
  6. doi request reprint Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
  7. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
  8. doi request reprint Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice
    Gabriel Vallecillo
    Department of Internal Medicine, Hospital del Mar, Barcelona, Spain
    AIDS Res Hum Retroviruses 28:165-70. 2012
  9. doi request reprint Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
  10. ncbi request reprint Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    J Antimicrob Chemother 61:206-9. 2008

Detail Information

Publications29

  1. ncbi request reprint Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir
    Josep M Llibre
    Internal Medicine Department, Hospital de Calella, Barcelona, Spain
    AIDS 20:1407-14. 2006
    ..To describe the 12-month evolution of lipid profile in HIV-infected virologically suppressed patients substituting tenofovir for stavudine...
  2. ncbi request reprint [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]
    Josep Maria Llibre-Codina
    Servicio de Medicina Interna, Hospital Sant Jaume, Calella, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:98-107. 2007
    ..To estimate the impact of toxicity related to nucleoside analogue reverse transcriptase inhibitors (NRTI) on the total cost of medical care in HIV-1-infected patients...
  3. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
    ....
  4. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  5. doi request reprint Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Antimicrob Chemother 67:1462-9. 2012
    ..To assess the most frequent resistance-associated mutations (RAMs) to lopinavir/ritonavir in a cohort of patients attended in daily practice...
  6. doi request reprint Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
    ..Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids...
  7. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  8. doi request reprint Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice
    Gabriel Vallecillo
    Department of Internal Medicine, Hospital del Mar, Barcelona, Spain
    AIDS Res Hum Retroviruses 28:165-70. 2012
    ..03) with an increase in HDL-cholesterol (p=0.01) over 48 weeks. The combination of nevirapine plus cTDF/FTC showed a high virological efficacy without unexpected toxicities as a first-line treatment in a routine clinical practice...
  9. doi request reprint Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
    ..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated...
  10. ncbi request reprint Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    J Antimicrob Chemother 61:206-9. 2008
    ..To determine the feasibility and outcomes of long-distance interactive expert advice for treatment-experienced patients...
  11. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  12. pmc Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    PLoS ONE 8:e70201. 2013
    ..Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited...
  13. doi request reprint [Etravirine: genetic barrier and resistance development]
    Josep M Llibre
    Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 27:32-9. 2009
    ..4) in up to 1 out of every 3 samples analyzed. The early withdrawal of first-generation NNRTIs in patients with virological failure is essential to avoid the accumulation of mutations that could compromise the activity of this drug...
  14. doi request reprint Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Germans Trias, Universitat Autonoma of Barcelona, Barcelona, Spain
    Clin Infect Dis 50:872-81. 2010
    ..Determining the most active drugs and successfully combining them is the key challenge in salvage regimens...
  15. doi request reprint Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals
    Arkaitz Imaz
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Antimicrob Chemother 66:358-62. 2011
    ..The advent of new antiretrovirals has expanded the therapeutic options for multiple drug-resistant HIV-1 infection. The role of recycled nucleoside reverse transcriptase inhibitors (NRTIs) in this scenario remains uncertain...
  16. ncbi request reprint Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy
    Gabriel V Sanchez
    Department of Internal Medicine, Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr HIV Res 10:356-63. 2012
    ..We describe the effectiveness of HAART provided in a drug abuse outpatient treatment facility through a comprehensive integrated care that includes medical, drug dependence, and psychosocial support...
  17. doi request reprint [Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]
    Josep M Llibre
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 28:615-20. 2010
    ..Excluding those cases that require a particular dose adjustment, FDCA are a preferred treatment option and their use must be strongly recommended in all scenarios where the components included in the combination are preferred drugs...
  18. doi request reprint Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:2358-62. 2013
    ..Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence...
  19. ncbi request reprint From TMC114 to darunavir: five years of data on efficacy
    Josep M Llibre
    HIV Unit and Lluita contra la SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Rev 15:112-21. 2013
    ..The present article summarizes the clinical implications of the key data on efficacy of darunavir...
  20. doi request reprint Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries
    Josep M Llibre
    University Hospital Germans Trias i Pujol, Badalona, Barcelona, Universitat Autonoma de Barcelona, Barcelona, Spain
    Scand J Infect Dis 45:635-44. 2013
    ..In developed countries with free access to health care, primary chemoprophylaxis with co-trimoxazole, and antiretroviral treatment, Pneumocystis pneumonia (PCP) in HIV-infected subjects should be restricted to undiagnosed late presenters...
  21. ncbi request reprint First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better
    Josep M Llibre
    Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Rev 11:215-22. 2009
    ....
  22. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  23. ncbi request reprint [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment]
    Josep M Llibre
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:17-22. 2008
    ..In both cases, intensification of ART with raltegravir could provide beneficial effects on the speed of elimination of the HIV-1 reservoir...
  24. pmc Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain
    Josep M Llibre
    HIV Unit, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain Lluita contra la SIDA Foundation, Badalona, Barcelona, Spain
    Clinicoecon Outcomes Res 5:215-21. 2013
    ..Switching antiretroviral drugs for others that have the same efficacy and safety profile at a lower cost (cost-reduction measures, CRM) could prove to be a valid means of generating savings...
  25. doi request reprint [Lymphogranuloma venereum proctocolitis in men with HIV-1 infection]
    Eva Heras
    Servicio de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 29:124-6. 2011
    ..We present a series of 15 cases with lymphogranuloma venereum (LGV) with the aim of evaluating the response to a 21-day oral course of doxycycline (100mg twice daily)...
  26. ncbi request reprint Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study
    Hernando Knobel
    Department of Internal Medicine, Infectious Diseases, Hospital del Mar, Barcelona, Spain
    J Acquir Immune Defic Syndr 37:1276-81. 2004
    ..The use of antihistamines remains unclear in this setting. A double-blind placebo-controlled study was performed to evaluate the efficacy of cetirizine in the prevention of nevirapine rash...
  27. ncbi request reprint Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study
    Vicenc Falco
    Infectious Disease Department, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 49:26-31. 2008
    ....
  28. ncbi request reprint Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
    Josep M Llibre
    Lluita contra la SIDA Foundation HIV Unit, University Hospital Germans Trias i Pujol, Badalona, Spain
    AIDS Rev 14:168-78. 2012
    ..Many HIV-1-infected patients who are treatment-naive or treatment-experienced with susceptible virus will potentially have more options to reduce pill burden and optimize dosage schedules with one pill once-daily regimens...
  29. ncbi request reprint Severe interaction between ritonavir and acenocoumarol
    Josep M Llibre
    Internal Medicine Department, Hospital Sant Jaume, Barcelona, Spain
    Ann Pharmacother 36:621-3. 2002
    ..To report a clinically severe interaction between ritonavir (RTV) and acenocoumarol resulting in a decrease in the anticoagulant effect severe enough to eventually preclude RTV administration...